Eugenia M. Dragunsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eugenia M. Dragunsky has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Inessa S. Levenbook
Center for Biologics Evaluation and Research, FDA, Kensington, MD, Central Institute for Experimental Animals, Kawasaki, Japan
3 shared publications- Konstantin Chumakov
George Washington University, USA
3 shared publications Rolf E. Taffs
Center for Biologics Evaluation and Research, FDA, Kensington, MD, Central Institute for Experimental Animals, Kawasaki, Japan
3 shared publicationsTatsuji Nomura
3 shared publicationsDavid M Asher
CBER/FDA, Rockville, USA
2 shared publicationsDavid M. Asher
Center for Biologics Evaluation and Research, FDA, Kensington, MD, Central Institute for Experimental Animals, Kawasaki, Japan
2 shared publications
Latest Publications
- Open Access
- 15 October 2004
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 190 (8) , 1404-1412
Evaluation of Immunogenicity and Protective Properties of Inactivated Poliovirus Vaccines: A New Surrogate Method for Predicting Vaccine Efficacy
An assay for the evaluation of protective properties of inactivated poliovirus vaccines (IPVs) in transgenic (Tg) mice susceptible to poliovirus has
- 15 October 2004
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 190 (8) , 1404-1412
Open AccessEvaluation of Immunogenicity and Protective Properties of Inactivated Poliovirus Vaccines: A New Surrogate Method for Predicting Vaccine Efficacy
An assay for the evaluation of protective properties of inactivated poliovirus vaccines (IPVs) in transgenic (Tg) mice susceptible to poliovirus has
- 16 May 2003
- Vol. 81 (4) , 251-60
Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study.
Extensive WHO collaborative studies were performed to evaluate the suitability of transgenic mice susceptible to poliovirus (TgPVR mice, strain 21, bred and provided by the Central Institute for Experimental Animals, Japan) as an alternative to monkeys in the neurovirulence test (NVT) of oral poliovirus vaccine (OPV). Nine laboratories participated in the collaborative study on testing neurovirulence of 94 preparations of OPV and vaccine derivatives of all three serotypes in TgPVR21 mice. Statistical analysis of the data demonstrated that the TgPVR21 mouse NVT was of comparable sensitivity and reproducibility to the conventional WHO NVT in simians. A statistical model for acceptance/rejection of OPV lots in the mouse test was developed, validated, and shown to be suitable for all three vaccine types. The assessment of the transgenic mouse NVT is based on clinical evaluation of paralysed mice. Unlike the monkey NVT, histological examination of central nervous system tissue of each mouse offered no advantage over careful and detailed clinical observation. Based on data from the collaborative studies the WHO Expert Committee for Biological Standardization approved the mouse NVT as an alternative to the monkey test for all three OPV types and defined a standard implementation process for laboratories that wish to use the test. This represents the first successful introduction of transgenic animals into control of biologicals.
- 16 May 2003
- Vol. 81 (4) , 251-60
Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study.
Extensive WHO collaborative studies were performed to evaluate the suitability of transgenic mice susceptible to poliovirus (TgPVR mice, strain 21, bred and provided by the Central Institute for Experimental Animals, Japan) as an alternative to monkeys in the neurovirulence test (NVT) of oral poliovirus vaccine (OPV). Nine laboratories participated in the collaborative study on testing neurovirulence of 94 preparations of OPV and vaccine derivatives of all three serotypes in TgPVR21 mice. Statistical analysis of the data demonstrated that the TgPVR21 mouse NVT was of comparable sensitivity and reproducibility to the conventional WHO NVT in simians. A statistical model for acceptance/rejection of OPV lots in the mouse test was developed, validated, and shown to be suitable for all three vaccine types. The assessment of the transgenic mouse NVT is based on clinical evaluation of paralysed mice. Unlike the monkey NVT, histological examination of central nervous system tissue of each mouse offered no advantage over careful and detailed clinical observation. Based on data from the collaborative studies the WHO Expert Committee for Biological Standardization approved the mouse NVT as an alternative to the monkey test for all three OPV types and defined a standard implementation process for laboratories that wish to use the test. This represents the first successful introduction of transgenic animals into control of biologicals.
- 1 April 1998
- Published by Springer Nature in Pediatric Research
- Vol. 43 (4) , 143
Molecular consistency monitoring of live viral vaccines ♦ 823
- 1 April 1998
- Published by Springer Nature in Pediatric Research
- Vol. 43 (4) , 143
Molecular consistency monitoring of live viral vaccines ♦ 823
- 1 April 1997
- Published by Springer Nature in Pediatric Research
- Vol. 41 (4) , 131
Potency Test of Inactivated Poliovirus Vaccine in Transgenic Mice Expressing Human Poliovirus Receptor. • 772
- 1 April 1997
- Published by Springer Nature in Pediatric Research
- Vol. 41 (4) , 131
Potency Test of Inactivated Poliovirus Vaccine in Transgenic Mice Expressing Human Poliovirus Receptor. • 772
- Open Access
- 1 February 1997
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 175 (2) , 441-444
Inactivated Poliovirus Vaccine Protects Transgenic Poliovirus Receptor Mice against Type 3 Poliovirus Challenge
Transgenic (Tg) mice expressing the human poliovirus receptor (PVR) were vaccinated with inactivated poliovirus vaccine (IPV) and evaluated for induced immunity against type 3 poliomyelitis. One injection of monovalent type 3 IPV elicited protective immunity against wild-type poliovirus. In contrast, 2 injections of trivalent IPV were required for protection. Neutralizing antibody response and protection were vaccine dose-dependent. Administration of polio-immune mouse plasma protected unimmunized mice, demonstrating that neutralizing antibody was sufficient for immunity. IPV heated to remove its D antigen component did not induce protection in Tg PVR mice. IPV derived from a wild-type poliovirus strain gave better protection against wild-type viral challenge than IPV derived from an attenuated poliovirus strain. The newly developed Tg PVR mouse-protection test may be useful in evaluating existing IPV potency tests and for attempts to improve formulations of trivalent IPV or combined vaccines for childhood immunization schedules.
- 1 February 1997
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 175 (2) , 441-444
Open AccessInactivated Poliovirus Vaccine Protects Transgenic Poliovirus Receptor Mice against Type 3 Poliovirus Challenge
Transgenic (Tg) mice expressing the human poliovirus receptor (PVR) were vaccinated with inactivated poliovirus vaccine (IPV) and evaluated for induced immunity against type 3 poliomyelitis. One injection of monovalent type 3 IPV elicited protective immunity against wild-type poliovirus. In contrast, 2 injections of trivalent IPV were required for protection. Neutralizing antibody response and protection were vaccine dose-dependent. Administration of polio-immune mouse plasma protected unimmunized mice, demonstrating that neutralizing antibody was sufficient for immunity. IPV heated to remove its D antigen component did not induce protection in Tg PVR mice. IPV derived from a wild-type poliovirus strain gave better protection against wild-type viral challenge than IPV derived from an attenuated poliovirus strain. The newly developed Tg PVR mouse-protection test may be useful in evaluating existing IPV potency tests and for attempts to improve formulations of trivalent IPV or combined vaccines for childhood immunization schedules.
- 1 April 1996
- Published by Springer Nature in Pediatric Research
- Vol. 39 (4) , 166
RECENT ADVANCES IN SAFETY TESTING OF LIVE ORAL POLIOVIRUS VACCINES. • 979
- 1 April 1996
- Published by Springer Nature in Pediatric Research
- Vol. 39 (4) , 166
RECENT ADVANCES IN SAFETY TESTING OF LIVE ORAL POLIOVIRUS VACCINES. • 979